Search Results

You are looking at 1 - 10 of 158 items for :

  • "interleukin-6" x
Clear All
Acta Microbiologica et Immunologica Hungarica
Authors: Renátó Kovács, Anita Czudar, László Horváth, Levente Szakács, László Majoros and József Kónya

Romani, L., Mencacci, A., Cenci, E., Spaccapelo, R., Toniatti, C., Puccetti, P., Bistoni, F., Poli, V.: Impaired neutrophil response and CD4+ T helper cell 1 development in interleukin 6-deficient mice infected with Candida albicans . J Exp Med 183

Open access

Neuroimmunomodulat 1995 2 241 248 Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B: Elevated levels of interleukin-6 are reduced in serum and subcutaneous adipose tissue of

Restricted access
Orvosi Hetilap
Authors: Éva Görbe, Judit Jeager, Bálint Nagy, Ágnes Harmath, Erik Hauzman, Ervin Hruby, Barbara Kőhalmi, Mónika Perlaki, Lilla Sassi and Attila Rab

Hatzidaki, E., Gourgiotis, D., Manoura, A.: Interleukin-6 in preterm premature rupture of membranes as an indicator of neonatal outcome. Acta Obst. Gyn. Scand., 2005, 84 , 632–638. Manoura A

Restricted access

1067 1074 Taga, T., Kishimoto, T. (1997) Gp 130 and the interleukin-6 family of cytokines. Ann. Rev. Immunol. 15 , 797-819. Gp 130 and the interleukin

Restricted access
Acta Veterinaria Hungarica
Authors: József Szabó, Emese Andrásofszky, Tamás Tuboly, András Bersényi, Andrea Weisz, Nikoletta Hetényi and István Hullár

The objective of this study was designed to test whether supplementation of the diet with arginine (Arg) or glutamine (Gln) or their combination influences the production, organ weights and humoral immune response of broilers. A total of 432 one-day-old male Ross 308 broiler chickens were divided into 6 treatment groups: control, Arg-0.5%, Arg-1%, Gln-0.5%, Gln-1% and Arg-0.5%+Gln-0.5%. Drinking water and feed were provided ad libitum. On day 18 of the experiment 50% of chickens in each treatment group were immunised with bovine serum albumin. Ten and 21 days after immunisation blood samples were collected to determine the anti-albumin IgY titre, interleukin 6 (IL6) and interferon gamma (IFNG) and to measure the weight of the liver, spleen, bursa of Fabricius and thymus. Arg or Gln supplementation of the diets influenced neither the production nor the organ weights until 18 days of age. Between 18 and 39 days of age both Arg (0.5% and 1%) and Arg + Gln supplementation improved the feed conversion ratio (FCR) by 3.7%, 6.3% and 4.9%, respectively, while Gln-1% worsened it by 15%. Immunisation slightly (−0.79%) depressed the body weight gain of broilers fed the control diet, which was significantly improved by both Arg (0.5 or 1%) and Arg + Gln supplementation. Immunisation increased the weight of the spleen, bursa and thymus and decreased that of the liver. Supplementation with 1% Gln depressed (−5.13%) the body weight gain of the immunised chickens but strongly stimulated the immune response. Supplementations with Arg and Gln did not influence the IL6 and IFNG level of the blood; however, on day 10 after immunisation these two parameters showed a negative correlation with each other. Regarding production, organ weights and immunity, Arg supplementation should be recommended in the grower phase, while Gln supplementation can be useful in pullets raised for egg production, where a good immune response to vaccinations is an important factor.

Restricted access
Orvosi Hetilap
Authors: Béla Gyarmati, Eszter Szabó, Balázs Szalay, Áron Cseh, Noémi Czuczy, Gergely Toldi, Barna Vásárhelyi and Zoltán Takáts

Lee, P., Peng, H., Gelbart, T. és mtsai: Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc. Natl. Acad. Sci., 2005, 102 , 1906–1910. Gelbart T

Open access
Orvosi Hetilap
Authors: Botond Lakatos, László Gopcsa, Enikő Gondos, Alexandra Riczu, Zsuzsa Várnai, Éva Nagy, Eszter Molnár, Gabriella Bekő, Ilona Bobek, Péter Reményi, János Szlávik, János Sinkó and István Vályi-Nagy

] 5 Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int J

Open access
Orvosi Hetilap
Authors: Ilona Bobek, László Gopcsa, Marienn Réti, Gabriella Bekő, Lilla Hancz, Botond Lakatos, Eszter Molnár, Sándor Nagy, Péter Reményi, Gabriella Sebestyén, János Sinkó, János Szlávik, Miklós Szolnoky and István Vályi-Nagy

Zhang C, Wu Z, Li JW, et al. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist tocilizumab may be the key to reduce the mortality. Int Antimicrobiol Agents 2020

Open access
Clinical and Experimental Medical Journal
Authors: Judit Jeager, Zsófia Schuler, Attila Molvarec, Mónika Perlaki, Lilla Sassi, Barbara Kőhalmi, Mihály Silhavy, Ágnes Harmath, János Rigó and Éva Görbe

Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia Pediatrics 116 1353 – 1360 . [22]. P. von Bismarck A. Claass C. Schickor 2008 Altered pulmonary interleukin-6 signaling in preterm

Restricted access
Acta Veterinaria Hungarica
Authors: Andrzej Rychlik, Renata Nieradka, Małgorzata Kander, Marcin Nowicki, Michał Wdowiak and Anna Kołodziejska-Sawerska

. (1999): Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease. J. Gastroenterol. Hepatol. 14 , 987–996. Kaneshiro K. Interleukin-6 and

Restricted access